Advent Life Sciences

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Relief Cardiovascular is a medical technology company focused on developing an innovative smart implant aimed at treating congestive heart failure. The company's implantable device is designed to monitor blood flow and alleviate congestion in the heart, thereby improving health outcomes for patients suffering from this condition. By providing a targeted treatment option, Relief Cardiovascular aims to enhance the quality of life for individuals with heart failure.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Argá Medtech is a developer of an innovative cardiac ablation system specifically designed for the treatment of cardiac arrhythmias, including ventricular tachycardia. The company utilizes a proprietary coherent sine-burst electroporation technology that enhances power and depth during procedures. This advanced system features an innovative catheter design that eliminates the need for multiple exchanges, offering improved flexibility and efficiency in clinical settings. By streamlining the treatment process, Argá Medtech aims to enable healthcare professionals to achieve better therapeutic outcomes for patients suffering from arrhythmias.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

PIC Therapeutics, Inc. is a biotechnology company dedicated to advancing cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and headquartered in Boston, Massachusetts, the company develops precision-based therapeutics that target the master switch of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This innovative approach has the potential to simultaneously address multiple oncogenic drivers, paving the way for a new generation of cancer therapies that could significantly enhance patient outcomes.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Wondr Medical is a London-based company established in 2016 that operates a platform designed to connect health professionals worldwide. Its primary objective is to enhance discovery, innovation, and collaboration within the global health network. The platform facilitates the generation of new ideas and the expansion of professional networks, while also aiding in the discovery of medical events and job opportunities. By providing a space for professional teams to share their work and stay informed, Wondr Medical aims to streamline communication and collaboration among medical professionals, ultimately advancing the field of healthcare.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Amphista Therapeutics Limited is a biopharmaceutical company founded in 2017 and located in Motherwell, United Kingdom. It specializes in developing targeted protein degradation technology aimed at creating innovative cancer therapeutics. The company focuses on harnessing the body's natural processes to selectively degrade and eliminate disease-causing proteins. By advancing next-generation therapeutics, Amphista seeks to improve treatment efficacy for various diseases, particularly cancer, by modulating the abundance of proteins responsible for disease progression. This strategic approach aims to enhance patient outcomes and contribute to the advancement of therapeutic options in oncology.

Wiz, Inc. is a cybersecurity company founded in 2020, with headquarters in Palo Alto, California, and an additional office in Tel Aviv, Israel. The company specializes in cloud security, providing enterprises with a platform that enables them to identify security issues within their public cloud infrastructure. Wiz's innovative solution offers a comprehensive, cloud-native visibility tool that analyzes the entire cloud environment, delivering a 360-degree view of security risks across various platforms, including clouds, containers, and workloads. The platform utilizes actionable, graph-based analysis to facilitate in-depth risk assessment and root cause analysis without the need for agents, allowing organizations to enhance their security posture effectively.

Highlight Therapeutics is a private, clinical-stage company focused on developing RNA-based immuno-oncology therapies aimed at treating cancer. The company’s innovative therapies mimic the effects of viral infections to enhance the efficacy of existing cancer treatments, thereby facilitating faster tumor recovery in patients. By leveraging the potential of immuno-oncology, Highlight Therapeutics seeks to improve patient outcomes and contribute to advancements in cancer care.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), an essential enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage, working to create a series of first-in-class molecules that aim to reactivate this vital tumor suppressor. With proprietary development tools, Rappta Therapeutics is enhancing its capacity for rational drug design, thus providing therapeutic options for a variety of cancer types and certain important non-oncology conditions.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

PIC Therapeutics, Inc. is a biotechnology company dedicated to advancing cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and headquartered in Boston, Massachusetts, the company develops precision-based therapeutics that target the master switch of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This innovative approach has the potential to simultaneously address multiple oncogenic drivers, paving the way for a new generation of cancer therapies that could significantly enhance patient outcomes.

Amphista Therapeutics Limited is a biopharmaceutical company founded in 2017 and located in Motherwell, United Kingdom. It specializes in developing targeted protein degradation technology aimed at creating innovative cancer therapeutics. The company focuses on harnessing the body's natural processes to selectively degrade and eliminate disease-causing proteins. By advancing next-generation therapeutics, Amphista seeks to improve treatment efficacy for various diseases, particularly cancer, by modulating the abundance of proteins responsible for disease progression. This strategic approach aims to enhance patient outcomes and contribute to the advancement of therapeutic options in oncology.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

KaNDy Therapeutics is a biopharmaceutical company specializing in the development of non-hormonal treatments for various symptoms associated with menopause, including hot flashes and nighttime awakenings. Founded in 2017 and based in Stevenage, United Kingdom, the company focuses on providing effective therapies for moderate to severe post-menopausal vasomotor symptoms. Its lead product, NT-814, addresses chronic debilitating conditions related to female sex hormones, offering a viable alternative for patients seeking relief without hormonal interventions. As a subsidiary of Bayer Aktiengesellschaft, KaNDy Therapeutics aims to improve the quality of life for women experiencing hormone-related challenges.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the pressing issue of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound that is currently undergoing Phase III clinical trials. Sulopenem is designed for both oral and intravenous use and aims to treat various serious infections, including uncomplicated and complicated urinary tract infections as well as complicated intra-abdominal infections. The company’s mission is to significantly improve the lives of patients affected by serious and life-threatening diseases by providing effective solutions to antibiotic resistance.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Aleta Biotherapeutics, Inc., founded in 2015 and based in Natick, Massachusetts, is an immuno-oncology company dedicated to developing innovative cellular therapeutics aimed at addressing a wide range of cancer indications. The company's focus is on transforming cellular therapies to target various tumor types, including challenging and often intractable solid tumors. By advancing these therapeutic approaches, Aleta Biotherapeutics seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the fight against cancer.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Capella BioScience is engaged in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAbs targeting oncology, autoimmune diseases, and other medical conditions. Capella BioScience collaborates with biotechnology firms and academic institutions to enhance its research and development efforts, aiming to advance innovative therapeutic solutions in the medical field.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.

Calcico Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in April 2012. It focuses on developing novel small molecule drugs specifically targeting calcium-release activated channels (CRAC) to address autoimmune and inflammatory disorders. The company has established proprietary methods for selective CRAC channel screening and molecule characterization, positioning itself uniquely in the biotechnology sector. Calcico Therapeutics aims to create potent and selective CRAC channel inhibitors to treat various conditions, including atopic dermatitis, where there is substantial evidence linking CRAC channels to human disease. Through its innovative approach, Calcico seeks to overcome challenges faced by pharmaceutical companies in achieving effective CRAC channel inhibition.

gmp-orphan (GMPO), it is their mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Their experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.

Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.

Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Avidex is an award-winning full-service audiovisual firm that specializes in designing, integrating, and managing audiovisual solutions for commercial and healthcare clients across the United States. The company partners with architects, contractors, consultants, educators, and executives to create a variety of spaces including boardrooms, videoconference rooms, auditoriums, training facilities, and digital signage projects. With over 130 employees, Avidex provides comprehensive support services, equipment procurement, and rental options. The company has successfully completed projects in more than a dozen countries and over 26 states within the U.S., making it a single source for all audiovisual needs.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

CardiAQ Valve Technologies is a privately held company dedicated to advancing heart valve replacement procedures. Its primary focus is on developing innovative techniques for transcatheter mitral valve implantation (TMVI), aiming to enable physicians to implant mitral valves within a beating heart without the need for open-heart surgery.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Ubiquisys is a mobile communications company that specializes in designing and developing devices for mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks, delivering 3G coverage in these environments. Ubiquisys also provides convergence solutions aimed at the wireless-wireline convergence technology market, enhancing the integration of mobile and fixed-line services. Through its innovative products, Ubiquisys aims to improve mobile connectivity for users in various settings.

CN Creative, headquartered in the Bioscience Incubator at Manchester University in the UK, focuses on addressing global challenges linked to smoking and smoking-related illnesses through innovative and sustainable solutions. The company has developed a range of products and services aimed at smoking cessation and harm reduction. Its offerings include QuitDirect, an NHS-accredited provider of smoking cessation services, the Intellicig® electronic cigarette, and ECOpure, a line of proprietary high-purity nicotine preparations. Additionally, CN Creative offers NRT Direct, which supplies traditional nicotine replacement therapy products and support services for both public and private smoking cessation programs. Currently, the Nicadex(TM) electronic inhaler, a nicotine replacement therapy product, is in clinical development for use in medically supervised smoking cessation initiatives.

Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Ampla Pharmaceuticals designs and develops biopharmaceutical drugs. The company was incorporated in 2006 and is based in La Jolla, California.

Vitrue is a provider of social media marketing solutions designed for marketers, agencies, and publishers. The company offers a comprehensive cloud-based platform that enables brands to effectively manage their social marketing efforts across various networks, including Facebook, Twitter, Google+, and YouTube. Vitrue's award-winning Social Relationship Management (SRM) platform supports over one billion social connections globally, managing more than 4,500 social accounts in over 100 countries. Its services include promotional programs, branded community development, and syndicated brand applications, along with centralized data and member management, strategic consultation, and event marketing integration. Vitrue aims to maximize the marketing potential of social media for its clients while ensuring security and scalability in its operations.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Cellnovo is a medical device company focused on diabetes management. The company develops and markets an integrated system that connects various components of diabetes care through mobile technology. Its product portfolio includes a cordless micro-pump, an integrated monitoring device, and a cellular handset equipped with a touch screen and an embedded blood glucose meter. This innovative system allows for automatic data transmission, enabling patients and healthcare providers to effectively monitor the patient's condition in real-time.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Ubiquisys is a mobile communications company that specializes in designing and developing devices for mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks, delivering 3G coverage in these environments. Ubiquisys also provides convergence solutions aimed at the wireless-wireline convergence technology market, enhancing the integration of mobile and fixed-line services. Through its innovative products, Ubiquisys aims to improve mobile connectivity for users in various settings.

AmberFin is a provider of content-based software services tailored for media and entertainment companies. The company specializes in maximizing the value of TV, film, and video content, streamlining the process from capture to distribution. By utilizing its technology, AmberFin helps content owners enhance revenues, reduce operational costs, save time, and address compatibility issues. A key offering is AmberFin iCR, which features Emmy-award winning technology that transforms existing content into formats that meet customer demands. As an open standards platform, AmberFin iCR digitizes and transforms both new and archived content, delivering high-quality visuals at smaller file sizes across various distribution channels, including the Internet, video on demand, television, and mobile devices.

OpenCloud Limited is a telecommunications company founded in 2000 and headquartered in Cambridge, United Kingdom, with additional offices in New Zealand, Spain, Singapore, Indonesia, and Brazil. The company specializes in providing service differentiation and network solutions for wireline and mobile operators, including mobile virtual network operators (MVNOs). OpenCloud offers a range of products, including the Rhino telecom application server, which supports the development and delivery of services across multiple network technologies, and various solutions tailored for Voice over LTE and GSM applications. Their product suite includes tools for real-time charging, service interaction, and application development, enabling operators to manage and customize their service offerings efficiently. OpenCloud also provides professional services such as solution consulting, integration, and support. Their clientele spans multinational groups, large operators, and independent operators across diverse regions, including the Americas, Europe, and Asia, focusing on enhancing the interoperability and efficiency of telecommunications services. As of 2017, OpenCloud operates as a subsidiary of Metaswitch Networks Ltd.

Ubiquisys is a mobile communications company that specializes in designing and developing devices for mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks, delivering 3G coverage in these environments. Ubiquisys also provides convergence solutions aimed at the wireless-wireline convergence technology market, enhancing the integration of mobile and fixed-line services. Through its innovative products, Ubiquisys aims to improve mobile connectivity for users in various settings.

Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.

Avila Therapeutics is a biotechnology company based in Waltham, Massachusetts, focused on the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. The company is known for its small molecule hepatitis C virus protease inhibitor, AVL-181. Established in 2006, Avila Therapeutics has formed a strategic alliance with Sanofi-Aventis to enhance its research and development efforts. As of 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation, continuing its commitment to advancing innovative therapeutic solutions.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.

Dailymotion is a video-sharing platform launched in 2005 that focuses on providing a diverse range of content, including news, sports, music, entertainment, comedy skits, political debates, and gaming live-streams. With a global audience of 300 million users, Dailymotion emphasizes premium content sourced from trusted publishers, having revamped its user experience in 2017. The platform collaborates with significant global content partners such as Universal Music Group, BBC News, and VICE, among others. It features a sophisticated video player that ensures high-quality viewing experiences across over 30,000 channels, allowing publishers to monetize their video content effectively. Dailymotion facilitates an average of 600,000 uploads per month, connecting video-makers with audiences while supporting contextual advertising. The company is owned by Vivendi, a multinational media corporation based in Paris.

The Fizzback Group, founded in 2004, specializes in customer engagement solutions that empower businesses to capture and analyze customer feedback in real-time. By leveraging a unique artificial intelligence engine, Fizzback transforms customer comments into actionable insights, allowing companies to respond effectively to their clients' needs. This innovative approach not only helps organizations enhance their customer service but also drives economic benefits by increasing customer lifetime value and fostering positive word-of-mouth. The Fizzback solution effectively amplifies the voice of customers, providing companies with valuable information to improve their offerings and engagement strategies.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Foundry is a company with a 20-year history that specializes in computer graphics, visual effects, and 3D design software. The company develops award-winning products that enhance visual experiences and is dedicated to collaborating with creative professionals worldwide. Foundry's software is widely utilized in the production of visual effects for feature films, video-on-demand content, television shows, and commercials, enabling artists and designers to create stunning visual sequences. Through its innovative technology, Foundry continues to play a significant role in the design and visual industries.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Qype is a social network focused on user-generated reviews of businesses and locations, founded in 2005 by German entrepreneur Stephan Uhrenbacher. It features a comprehensive database that allows users to browse and discover highly rated places across Europe and beyond, covering more than 160,000 cities and towns in nine languages. Users can contribute by adding new locations, writing reviews, and sharing photos and videos. The platform also facilitates community engagement through message boards and groups. Qype is accessible via both its website and a mobile application, enabling users to find top-rated establishments near their current location.

OpenCloud Limited is a telecommunications company founded in 2000 and headquartered in Cambridge, United Kingdom, with additional offices in New Zealand, Spain, Singapore, Indonesia, and Brazil. The company specializes in providing service differentiation and network solutions for wireline and mobile operators, including mobile virtual network operators (MVNOs). OpenCloud offers a range of products, including the Rhino telecom application server, which supports the development and delivery of services across multiple network technologies, and various solutions tailored for Voice over LTE and GSM applications. Their product suite includes tools for real-time charging, service interaction, and application development, enabling operators to manage and customize their service offerings efficiently. OpenCloud also provides professional services such as solution consulting, integration, and support. Their clientele spans multinational groups, large operators, and independent operators across diverse regions, including the Americas, Europe, and Asia, focusing on enhancing the interoperability and efficiency of telecommunications services. As of 2017, OpenCloud operates as a subsidiary of Metaswitch Networks Ltd.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Orecon Ltd. is a company based in Bodmin, United Kingdom, that specializes in the development of innovative wave energy devices. Established in 2002, Orecon focuses on harnessing the ocean's immense power to generate sustainable and affordable electricity. The company is known for its oscillating water column technology and multi-resonant chamber wave energy devices, designed to efficiently convert wave energy into usable power. Its robust steel wave energy buoy is engineered to withstand tidal forces while minimizing movement caused by waves, ensuring reliability and effectiveness. Orecon is committed to environmental stewardship, prioritizing the health of ocean ecosystems while advancing clean energy solutions.

Wisair is a fabless semiconductor company providing single-chip based Ultra Wideband (UWB) and Wireless USB solutions for personal computing, consumer electronics, and mobile devices.

Moveme.com is an online platform that offers free, instant quotes for various moving-related services in the U.K. It serves as a marketplace connecting users with local moving service providers. The company covers a wide range of services, including removals, home insurance, and assistance with tradespeople. Additionally, it provides quotes for mortgage options, television, broadband services, and energy performance certificates, streamlining the moving process for users by consolidating multiple service needs in one portal.

Cellnovo is a medical device company focused on diabetes management. The company develops and markets an integrated system that connects various components of diabetes care through mobile technology. Its product portfolio includes a cordless micro-pump, an integrated monitoring device, and a cellular handset equipped with a touch screen and an embedded blood glucose meter. This innovative system allows for automatic data transmission, enabling patients and healthcare providers to effectively monitor the patient's condition in real-time.